Web Exclusives

Can Therapeutic Decisions Be Based on Cytogenetic Findings?
In recent years, a better understanding of the biology and molecular pathology of multiple myeloma (MM) has resulted in significant therapeutic milestones.
Read More

Considerations in Benefit Design for Multiple Myeloma
In this newsletter, we will discuss benefit design considerations for multiple myeloma, with a focus on treatment pathways and information technologies that can be used to improve patient care.
Read More

Bone Disease in Multiple Myeloma
In this fifth issue, we will focus on the economic implications of newer agents used to treat myeloma-related bone disease.
Read More

Side Effect Management in the Treatment of Multiple Myeloma
In this fourth issue, we will focus on the value of incorporating best practices for managing treatment-related toxicities.
Read More

Renal Impairment in Multiple Myeloma
In this third issue, we will be focusing on the impact of novel agents on myeloma-associated renal impairment.
Read More

Relevance of End Points in Clinical Trials for Multiple Myeloma
In this second issue, we will focus on the relevance of end points in clinical trials for myeloma.
Read More

The Importance of Cytogenetic Testing for Patients with Multiple Myeloma
This first newsletter will discuss guided therapeutic choices based on the presence of high-risk cytogenetic abnormalities.
Read More

Page 4 of 4

Subscribe to Value-Based Care in Neurology

Stay up to date with the latest news in neurology by subscribing to receive the free VBCN e‑Newsletter.